- Home
- DVAX vs XNCR Comparison
DVAX vs XNCR Comparison
Compare DVAX & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- XNCR
- Stock Information
- Founded
- DVAX 1996
- XNCR 1997
- Country
- DVAX United States
- XNCR United States
- Employees
- DVAX N/A
- XNCR N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- DVAX Health Care
- XNCR Health Care
- Exchange
- DVAX Nasdaq
- XNCR Nasdaq
- Market Cap
- DVAX 1.5B
- XNCR 1.5B
- IPO Year
- DVAX 2004
- XNCR 2013
- Fundamental
- Price
- DVAX $12.21
- XNCR $23.07
- Analyst Decision
- DVAX Buy
- XNCR Strong Buy
- Analyst Count
- DVAX 2
- XNCR 8
- Target Price
- DVAX $22.00
- XNCR $35.50
- AVG Volume (30 Days)
- DVAX 3.3M
- XNCR 498.6K
- Earning Date
- DVAX 11-07-2024
- XNCR 11-06-2024
- Dividend Yield
- DVAX N/A
- XNCR N/A
- EPS Growth
- DVAX N/A
- XNCR N/A
- EPS
- DVAX 0.15
- XNCR N/A
- Revenue
- DVAX $260,810,000.00
- XNCR $85,164,000.00
- Revenue This Year
- DVAX $23.13
- XNCR N/A
- Revenue Next Year
- DVAX $19.60
- XNCR $86.53
- P/E Ratio
- DVAX $80.80
- XNCR N/A
- Revenue Growth
- DVAX N/A
- XNCR N/A
- 52 Week Low
- DVAX $9.74
- XNCR $15.31
- 52 Week High
- DVAX $15.01
- XNCR $26.84
- Technical
- Relative Strength Index (RSI)
- DVAX 52.22
- XNCR 62.73
- Support Level
- DVAX $11.61
- XNCR $23.05
- Resistance Level
- DVAX $13.74
- XNCR $24.04
- Average True Range (ATR)
- DVAX 0.52
- XNCR 0.83
- MACD
- DVAX 0.09
- XNCR 0.10
- Stochastic Oscillator
- DVAX 32.80
- XNCR 68.65
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.